When announcing the large first-of-its-kind study links between genetics, cognition and psychiatric disorders in August, Lundbeck and partner 23andMe expected recruitment of the 25,000 participants to take around a year. Now, three months later, it has been completed thanks to huge interest from participants.
The very fast recruitment process means that we are already now getting initial demographic data about the study population and that we will be able to analyze the full data set instead of the planned interim analyses. Basically, we will learn faster from the study than originally anticipated. The recruitment speed illustrates a great interest in the patient community to participate in research to advance the knowledge of Major Depressive Disorder and Bipolar Disorder. This is of course very encouraging and we will be contemplating how to further leverage patients’ interest and commitment in future research activities.
Click to read the press release about the study.
About 23andMe, Inc.
23andMe, Inc. is the first and only direct-to-consumer genetic testing service with reports that meet the standard of the U.S. Food and Drug Administration (FDA). Founded in 2006, the mission of the company is to help people access, understand and benefit from the human genome. 23andMe, Inc. has two million customers worldwide, with 85 percent consented to participate in research. 23andMe, Inc. is located in Mountain View, CA. More information is available at www.23andMe.com.
The study will be conducted in the United States only. Participants must be 18-50 years old, live in the United States, have access to a desktop or laptop computer (smartphones and tablets will not work with this study), have been prescribed medication to treat MDD or Bipolar Depression, are willing to provide a saliva sample for DNA testing and are willing to complete monthly study sessions over the course of nine months. Participants' data is de-identified to preserve privacy.